Startups
For migraine and cluster headache pain gammaCore is an FDA-cleared, safe, and effective treatment.
Overview
Location
Australia
Employees
11-50
Phone
+1 888-903-2673
Mentions in press and media 12
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 20, 2022 | gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Neurobehavioral Outcomes in a Model of Traumatic Brain Injury | Pre-clinical trial demonstrates ability of nVNS to decrease amount of brain injury, decrease anxiety and improve motor function post injury |
| Jul 7, 2022 | electroCore, Inc. Announces Study of gammaCore Sapphire™ for the Treatment of Post-COVID Syndrome | Study to be initiated with Mayo Clinic’s Post-COVID Care Clinic subjects |
| May 24, 2022 | electroCore, Inc. Announces gammaCore™ Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain Centers | ROCKAWAY, N.J., May 24, 2022 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) will be available f... |
| Apr 19, 2022 | gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) Selected for Department of Defense Biotech Optimized for Operational Solutions and Tactics (BOOST) Program | If initial findings are confirmed, program calls for field-ready gammaCore™ nVNS devices in 2H-2023 |
| Mar 10, 2022 | electroCore Announces Fourth Quarter and Full Year 2021 Financial Results | Full year 2021 net sales of approximately $5.5 million increased 56% over $3.5 million for full year 2020 |
| Feb 9, 2022 | Data Presented at 2022 International Stroke Congress Suggests Role for Non-invasive Vagus Nerve Stimulation (nVNS) for Treatment of Acute Stroke | Clinical trial (n=69) suggests safety and feasibility of nVNS for the acute treatment of stroke. Relative ischemic lesion growth decreased by 65.9% with nVNS vs. sham treatment. |
| Feb 1, 2022 | electroCore, Inc. Announces Completion of Enrollment in the TRANSIT Study of non-Invasive Vagus Nerve Stimulation (nVNS) in Post-Operative Ileus | Data on 97-patient, randomized, sham-controlled study to be presented at medical congress later this year |
| Jan 11, 2022 | electroCore, Inc. Broadens Patient Access to gammaCore with Launch of U.S. Telehealth Portal and Online Store | E-Commerce platform allows patients to obtain prescriptions, purchase nVNS devices, and receive training |
| Sep 24, 2020 | electroCore Announces Agreement with UpScript, LLC to be Exclusive Online Telehealth Provider for gammaCore Sapphire™ CV | Comprehensive telehealth platform to facilitate the efficient procurement of gammaCore Sapphire™ CV (non-invasive vagus nerve stimulator) by known or suspected COVID-19 patients |
Show more
Reviews 0
FAQ about gammaCore Sapphire
What has the press written about gammaCore Sapphire?
Parsers VC has collected 12 articles mentioning gammaCore Sapphire, among them “gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Neurobehavioral Outcomes in a Model of Traumatic Brain Injury” (Oct 20, 2022) and “electroCore, Inc. Announces Study of gammaCore Sapphire™ for the Treatment of Post-COVID Syndrome” (Jul 7, 2022).
Is gammaCore Sapphire still active?
Yes, gammaCore Sapphire is active; its latest activity on Parsers VC dates from Jun 7, 2023.